INTRODUCTION {#S1}
============

Nepal is a developing country landlocked between China and India, with poor healthcare indicators.[@B1] The geography of the country varies from plain lands to high altitude mountains. A significant portion of the country has a poor transportation and infrastructure. The qualified medical doctors in the country often do not practice in the rural and remote areas and hence the rural patients rely upon local healthcare practitioners for their healthcare needs. The health posts and the primary health centers in the rural areas are manned by community health assistants who do not possess a medical qualification. In addition, the doctor-patient ratio in Nepal is also very low (1:23 000).[@B2] The hilly terrain, poor socioeconomic status, high cost of modern medicines and non-availability of qualified doctors in rural areas, limits the access to modern healthcare by the general public. These factors led to the flooding of a high number of retail pharmacies in the country. The number of retail pharmacies outnumbers the number of health centers.[@B3] The retail pharmacists do not collect a consultation charge unlike the medical doctors who opts a high consultation charges for every patient. All these factors collectively makes the retail pharmacies to be the first point of contact with the healthcare system by general public, thus giving a high opportunity for self-medication.[@B4] Self-medication is known to contribute to Adverse Drug Reactions (ADRs) either by the drug itself or by causing an interaction with a prescription drug. Moreover there is evidence that the retail pharmacists themselves prescribe and dispense medications.[@B5] The knowledge levels of retail pharmacists often goes beyond their technical skills and expertise.[@B6] These retail pharmacists usually has a two year Diploma in Pharmacy (D.Pharm) or four year Bachelor in Pharmacy (B. Pharm) qualifications. A few of them possess a two week orientation program conducted by the national drug regulatory authority of Nepal, which is considered as a minimum qualification for registering a retail pharmacy. All the above mentioned problems collectively increase the risk for ADRs in the community settings of Nepal.

The concept of ADR monitoring in Nepal is in the stage of infancy. However, the Department of Drug Administration (DDA), the national drug regulatory authority, has under taken steps to establish an ADR monitoring program in Nepal. In the year 2006, Nepal has been given a member status by the Uppsala Monitoring Center, Sweden, the WHO collaborating Center for International Drug Monitoring. The ministry of health and population has designated DDA as the national center for ADR monitoring.[@B7] Four regional centers are functioning under the national centers at present. These centers are located at teaching hospitals namely Tribhuvan University Teaching Hospital (TUTH) Kathmandu; Nepal Medical College, Kathmandu; KIST Medical College, Lalitpur; and Manipal Teaching Hospital (MTH) Pokhara, Nepal. These centers collect the ADR reports and send to the national center at DDA through the 'vigiflow online' (the WHO database) program.

The existing system of ADR monitoring in the country is beneficial only in reporting the ADRs that occur in hospital setups. This system remains unanswered for reporting ADRs that occur with over the counter (OTC) medications and in the ambulatory patient settings. This had led to the development of community based ADR reporting and monitoring system which could play an active role in collecting reports of ADRs occurring at the community level.[@B8] The regional pharmacovigilance center of Western Nepal has been involved in reporting the ADRs occurring in the MTH. The members from the department of hospital and clinical pharmacy, and pharmacology are involved in the center. In the beginning the center did not focus towards the ADRs occurring in the community. Recently, in the year 2008, the members of the center have decided to setup a community based Pharmacovigilance system in which the community pharmacists report the ADRs. The outcome of such an initiative taken by the center is presented in the present article. Thus, the study was conducted with the following objectives:

To collect the demographic details of the patients experiencing adverse drug reactions in the communityTo identify the common drugs causing the adverse drug reactionsTo identify the common types of adverse drug reactionsTo carry out the causality, severity and preventability assessments of the reported adverse drug reactions

METHODS {#S2}
=======

Study design: A cross sectional study evaluating the pattern of ADRs was carried out by analyzing the filled ADR reporting forms received from the community pharmacists ([Figure 1](#F1){ref-type="fig"}).

Selection of community pharmacists: The baseline KAP of 116 community pharmacists from Pokhara valley towards drug safety was evaluated using a validated (Cronbach alpha of 0.61) KAP questionnaire having 20 questions \[(knowledge=11, attitude=5 and practice=4) maximum possible score 40\]. Thirty community pharmacists with higher scores were selected for the training. Among these 30, six were initially tested as a pilot group ([Figure 1](#F1){ref-type="fig"}).

![Selection of participants and the study design](pharmpract-08-201-g001){#F1}

Development of ADR reporting form: An ADR reporting form was developed by the regional pharmacovigilance center and was used in the research. The reporting form had information on reporter, patient details and information on the reaction and medications. A pilot study was initially carried out with six community pharmacists and their inputs were taken while designing the ADR reporting form.[@B9]

Training the community pharmacists: The training for pilot group (six community pharmacists) included three sessions spreaded over two months, covering the basic information and expertise needed to identify and report ADRs by filling the ADR reporting forms. After completion of the training for pilot group, the test group also received three sessions of training similar to the pilot group but spreaded over six months duration.

Method of collecting ADR reports: The pharmacists from the regional pharmacovigilance center visited the trained community pharmacists every alternate day and collected the filled ADR reporting forms. Any additional help needed for the community pharmacists were provided by the pharmacovigilance center pharmacists.

Data analysis: All the ADRs reported to the regional pharmacovigilance centre by the community pharmacists were collected. The demographic details were analyzed. The causality, severity and preventability assessments were carried as per the Naranjo[@B10], Hartwig[@B11] and Modified Schumock and Thornton scales[@B12], respectively.

RESULTS {#S3}
=======

During the study period, 71 cases of ADRs from 71 patients were reported and the details are summarized below.

Demographic details of the patients experiencing ADRs: Among the total 71 patients, 52.1% (n=37) were males and the remaining 47.8 % (n=34) were females. Twenty two (30.9 %) of the patients were within 20 years of age, 50.7 % (n=36) were between 21 to 40 years of age, 14 % (n=10) were between 41-60 years of age and 4.2% (n=3) were more than 60 yrs of age.

Onset of the ADRs: In ten cases (14%), the patient was exposed to the suspected drug for less than a day; in 20 (28.1%) patients, 1-2 days; in 10 (14 %) patients, 3-4 days; in 10 (14 %) patients, 5-6 days; in 5 (7%) patients, 7-8 days; in 5 (7%) patients, more than 8 days in one (1.4 %) patients. The duration of use of the suspected drug was not available in 20 (28.1%) patients.

Suspected drug category causing ADRs: More number (42%) of ADRs was caused by Antibiotics/antibacterial class of drugs. Further details on the suspected drug categories responsible for causing the ADRs are listed in [Table 1](#T1){ref-type="table"}.

###### 

Suspected drug category causing ADRs (n=88)

  --------------------------- -------- ------------
  Drug category               Number   Percentage
  Antibiotics/antibacterial   37       42.0
  NSAIDs                      22       25
  Vitamins                    4        4.5
  Antiamoebics                4        4.5
  Antifungals                 3        3.4
  Antisecretory agents        4        4.5
  Sex hormones                4        4.5
  Miscellaneous               10       11.3
  --------------------------- -------- ------------

Top ten drugs causing the ADRs: Of the 71 reports, 10 were caused by the fixed dose combination (FDC) Ibuprofen/ paracetamol. The most common drugs responsible for causing the ADRs are listed in [Table 2](#T2){ref-type="table"}.

###### 

Top ten drugs causing the ADRs

  ------------------------------------------------------------------------ -------------
  Drugs                                                                    No. reports
  Tab. Ibuprofen/paracetamol combination                                   10
  Cap. Amoxycillin                                                         8
  Cap. Ampicillin/cloxacillin combination                                  6
  Tab. Metronidazole                                                       5
  Tab. Diclofenac                                                          5
  Inj. Ceftriazone                                                         4
  Inj. Gentamicin                                                          2
  Tab. Folic acid                                                          2
  Cap. Omeprazole                                                          2
  Tab. Paracetamol+phenylephedrine+ chlorpheniramine maleate combination   4
  ------------------------------------------------------------------------ -------------

Types of adverse drug reactions: The types of ADRs observed are listed in [Table 3](#T3){ref-type="table"}. System affected by adverse drug reactions (n=116): The most affected system by the ADRs was dermatological (37.9%; n=44), followed by gastrointestinal system (18.9%; n=22), cardiovascular (11.2%; n=13), central nervous system (7.7%; n=9), immune system (5.1%; n=6), ocular (4.3%; n=5), hematological (2.5%; n=3), endocrine (1.7%; n=2) and miscellaneous (10.3%; n=12).

###### 

Types of adverse drug reactions (n=116)

  ---------------------------------------- ---------------- ------------
  Reaction type                            No. of reports   Percentage
  Itching                                  20               17.2
  Vomiting                                 10               8.6
  Generalized edema                        10               8.6
  Macular rashes                           9                7.7
  Swelling                                 8                6.8
  Abdominal pain                           6                5.1
  Urticaria                                6                5.1
  Fever, rigor and chills                  5                4.3
  Tingling in body, giddiness              5                4.3
  Contact dermatitis                       4                3.4
  Generalized itchy maculopapular rashes   3                2.5
  Blurred vision                           2                1.7
  Diarrhea                                 2                1.7
  Shivering and feeling cold               3                2.5
  Swelling in upper and lower limbs        2                1.7
  Positive skin test                       1                0.8
  Sore throat/tonsillitis/fever            2                1.7
  Miscellaneous                            18               15.5
  ---------------------------------------- ---------------- ------------

Treatment of the reaction, action taken and outcome of the suspected ADRs: Of the 71 patients, 49 (69%) needed a medical treatment for managing the ADRs. Further details on various treatment methods, action taken and outcome of the suspected ADRs are listed in [Table 4](#T4){ref-type="table"}.

###### 

Treatment of the reaction, action taken and outcome of the reaction

  ---------------------------- -------------------- -------- ------------
  Features                     Parameters           Number   Percentage
  Treatment                    Medical treatment    49       69.0
  Non medical treatment        5                    7.0      
  Unknown                      17                   23.9     
  Outcome                      Recovered/resolved   27       38.0
  Not recovered/not resolved   3                    4.2      
  Unknown                      41                   57.7     
  Action taken                 Drug withdrawn       33       46.4
  Dose reduced                 2                    2.8      
  Dose increased               2                    2.8      
  Dose not changed             8                    11.2     
  Unknown                      26                   36.6     
  ---------------------------- -------------------- -------- ------------

Causality, severity and preventability of the reported ADRs: The causality assessment, severity assessment and preventability assessment of the reported ADRs are listed in [Table 5](#T5){ref-type="table"}.

###### 

Causality, severity and preventability of the reported ADRs (n=71)

  --------------------------------------------- ------------------------ ---------------- ------------
  Features                                      Parameters               No. of reports   Percentage
  Causality                                     Possible                 49               69.0
  Probable                                      22                       30.9             
  Definite                                      \-                       \-               
  Not carried out                               \-                       \-               
  Severity                                      Mild (Level 1)           19               26.7
  Mild (Level 2)                                50                       70.4             
  Moderate (Level 3)                            2                        2.8              
  Moderate \[Level 4(a)\]                       \-                       \-               
  Moderate \[Level 4(b)\]                       \-                       \-               
  Severe (Level 5)                              \-                       \-               
  Severe (Level 6)                              \-                       \-               
  Severe (Level 7)                              \-                       \-               
  Preventability                                Definitely preventable   46               64.7
  Probably preventable                          13                       18.3             
  Not preventable                               \-                       \-               
  Not carried out [\*](#t5fn1){ref-type="fn"}   12                       16.9             
  --------------------------------------------- ------------------------ ---------------- ------------

\* = We could not carryout the preventability assessment of these suspected ADRs due to the unavailability of adequate information.

DISCUSSION {#S4}
==========

Self medication is a common problem in both developed and developing countries.[@B13] In Nepal retail pharmacists are the first point of contact to the patients[@B2] and hence play an important role in the healthcare system. Data from Nepal suggest improper drug use by the retail pharmacists.[@B5],[@B14] They are known to diagnose, prescribe and dispense medications. Such activity of community pharmacists who had poor qualifications and training can lead to irrational drug use. It may results in ADRs. ADR is considered to be one of the major causes of mortality in developed countries.[@B15] In Nepal the concept of ADR reporting is new and there is paucity in the data regarding drug safety. A few studies that are already reported are hospital based studies.[@B16]-[@B18] In general, the health professionals in Nepal has a poor practice of ADR reporting to the national pharmacovigilance program. A preliminary study from the country reported a poor understanding among the clinicians, pharmacists and nurses regarding ADR reporting and pharmacovigilance.[@B19] The present study analyzed the pattern of ADRs reported by the community pharmacists to the regional pharmacovigilance center, Western Nepal. Thus, making it the first kind of its study in the country and from developing countries.

Upon training, the community pharmacy practitioners started reporting the ADRs to the regional pharmacovigilance center. During six months, they reported 71 ADR reports. The analysis of these 71 ADR reports revealed the sex distribution of the patients experiencing ADRs to be almost equal. In general, female are prone to cause ADRs.[@B20] It is however, difficult to generalize as the number of patients was low.

Analgesics were the second most common class of drugs implicated for causing ADRs. Analgesics have caused several ADRs including gastric problems. Many times, they are used as OTC by the general public. The community pharmacist can play an important role in minimizing these ADRs by providing simple information to the patients regarding the precautions to be taken while taking medicines like either before or after food accordingly, and having more water with the medicine. In Spain, a pharmacist mediated intervention at community pharmacies improved the practice of adequate gastroprotection for patients asking for NSAIDS.[@B21]

We found antibiotics to be the most common class of drugs causing ADRs. The irrational use of antibiotics/antibacterial by community pharmacy practitioners has already been demonstrated by researchers a decade ago in Nepal.[@B14] Moreover; in Nepal the community pharmacists dispense antimicrobials without a prescription. Few studies from the hospital settings in Nepal have already raised concerns regarding irrational antimicrobial use.[@B22]-[@B24] Though, it is a common problem in both hospital and community settings, the impact may be higher in the community since antimicrobials are available even without having a prescription.

We found the ibuprofen/paracetamol to have caused more number of ADRs. Use of ibuprofen/paracetamol combinations is common in Nepal.[@B25],[@B26] Since it is an OTC medication; very often the patients consider these medications to be very safe. However, this medication is not approved in many countries and hence not available. There is also a claim that this combination is irrational.[@B27] This finding suggests the need for more vigilance regarding the dispensing of OTC products by the retail pharmacists.

More number of ADRs reported was related to dermatological system suggesting topical ADRs. Topical ADRs are usually mild. However, they can contribute to significant economic loss 28 and impairment in quality of life of patients. Among the total 71 patients, 13 of them required medical treatment for ADRs and in 14 of the cases the suspected drugs were withdrawn. The skin and the mucosa are the commonest sites for initial presentation of many ADRs. In general, it is easy to identify a cutaneous ADR. The community pharmacy practitioners can play a vital role in minimizing the cutaneous ADRs by educating the patients regarding common early symptoms (eg, erythematous rash, edema, urticaria, mucosal erosions, itching, and burning of skin) especially during the start of the therapy.

Slightly more than two third (69%) of the ADRs required a medical treatment in managing the ADRs. Thus, there is an economic burden to the patient experiencing the ADR in addition to the suffering and impaired quality of life. A preliminary evaluation of the cutaneous ADRs reported to the regional pharmacovigilance center reported a cost burden of USD 1.58 (SD=1.41) for drug therapy.[@B28] Though this finding included the ADRs occurring in the hospital, it provides a rough idea on the economic impact of the ADRs in Nepal.

In this study, 46 (nearly 64.7%) of the total ADRs to be definitely preventable. It is well established that more than half of the ADRs are preventable with appropriate care.[@B29] Since the ultimate objective of a pharmacovigilance program is to minimize the occurrence of similar ADRs in the future; one should take adequate steps in preventing the ADRs.

Limitations: Our study was conducted for a short period of time (six months) and included only a few (30) community pharmacists. Similar studies covering more retail pharmacists for a longer period of time are needed to validate our finding. Moreover, there is high possibility of under reporting by the community pharmacists.

Future directions: The present study was preliminary one which evaluated the ADRs reporting pattern by community pharmacists in a developing country like Nepal. Similar training programs are needed for other community pharmacists in order to strengthen the program. In addition, measures have to be taken to sustain the program. This can be achieved by involvement of professional pharmacy associations in the country and commitment and vision from the national pharmacovigilance center. The community pharmacists should also be oriented to send the reports directly to the regional pharmacovigilance center in spite of the pharmacovigilance center staffs visiting the community pharmacists to collect the reports.

CONCLUSIONS {#S5}
===========

The study was successful in analyzing the pattern of ADRs reporting by retail pharmacists. The common class of drugs known to cause ADRs was antibacterial/ antibiotics. Ibuprofen/paracetamol combination was the drug responsible for more number of ADRs and the most common ADRs were related to dermatological system. Upon strengthening the community based pharmacovigilance system there can be more rational use of medicines in community. It will also help in minimizing the occurrence of ADRs in the community.
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